TSLA
Tesla
-- 442.530 NVDA
NVIDIA
-- 130.640 PLTR
Palantir
-- 71.510 SMCI
Super Micro Computer
-- 34.470 MSTR
MicroStrategy
-- 426.290 
NEWS
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
Wednesday, 11th December at 7:00 am
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. ("ImmunoGenesis"), a Houston-based clinical-stage biotechnology company developing science-driven immunotherapies. The collaboration focuses on the development of novel formulations utilizing PolyPid's experience with its proprietary PLEX Technology and ImmunoGenesis' potent STimulator of INterferon Genes (STING) agonist drug candidate to potentially enhance treatment for solid tumors.
Wednesday, 11th December at 7:00 am
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. ("ImmunoGenesis"), a Houston-based clinical-stage biotechnology company developing science-driven immunotherapies. The collaboration focuses on the development of novel formulations utilizing PolyPid's experience with its proprietary PLEX Technology and ImmunoGenesis' potent STimulator of INterferon Genes (STING) agonist drug candidate to potentially enhance treatment for solid tumors.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment